Last reviewed · How we verify

New Discovery LLC — Portfolio Competitive Intelligence Brief

New Discovery LLC pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
TDF treatment TDF treatment marketed Nucleotide reverse transcriptase inhibitor (NtRTI) Viral reverse transcriptase Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
  2. Humanity and Health Research Centre · 1 shared drug class
  3. ViiV Healthcare · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for New Discovery LLC:

Cite this brief

Drug Landscape (2026). New Discovery LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/new-discovery-llc. Accessed 2026-06-10.

Related